Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $247.9 million.

  • Avidity Biosciences' Total Liabilities rose 8046.6% to $247.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.9 million, marking a year-over-year increase of 8046.6%. This contributed to the annual value of $138.9 million for FY2024, which is 872.13% up from last year.
  • As of Q3 2025, Avidity Biosciences' Total Liabilities stood at $247.9 million, which was up 8046.6% from $176.3 million recorded in Q2 2025.
  • Avidity Biosciences' Total Liabilities' 5-year high stood at $247.9 million during Q3 2025, with a 5-year trough of $26.0 million in Q2 2021.
  • Over the past 5 years, Avidity Biosciences' median Total Liabilities value was $55.7 million (recorded in 2023), while the average stood at $89.8 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 392.67% in 2021, then skyrocketed by 14668.46% in 2024.
  • Avidity Biosciences' Total Liabilities (Quarter) stood at $46.2 million in 2021, then soared by 31.58% to $60.7 million in 2022, then skyrocketed by 110.44% to $127.8 million in 2023, then grew by 8.72% to $138.9 million in 2024, then surged by 78.46% to $247.9 million in 2025.
  • Its Total Liabilities stands at $247.9 million for Q3 2025, versus $176.3 million for Q2 2025 and $130.4 million for Q1 2025.